HAL Id: hal-02393327
https://hal-amu.archives-ouvertes.fr/hal-02393327
Submitted on 5 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of
sci-entific research documents, whether they are
pub-lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Metformin-Derived Hybrid Molecules for Glioblastoma
Treatment
Caroline Delehedde, Mathieu Chocry, Sophie Thétiot-Laurent, Françoise
Garrouste, Marcel Culcasi, Hervé Kovacic, Sylvia Pietri
To cite this version:
Caroline Delehedde, Mathieu Chocry, Sophie Thétiot-Laurent, Françoise Garrouste, Marcel Culcasi,
et al.. Metformin-Derived Hybrid Molecules for Glioblastoma Treatment. Proceedings, MDPI, 2019,
22 (1), pp.83. �10.3390/proceedings2019022083�. �hal-02393327�
Proceedings 2019, 22, 83; doi:10.3390/proceedings2019022083 www.mdpi.com/journal/proceedings
Abstract
Metformin-Derived Hybrid Molecules for
Glioblastoma Treatment
†
Caroline Delehedde
1,*, Mathieu Chocry
1,2, Sophie Thétiot-Laurent
1, Françoise Garrouste
2,
Marcel Culcasi
1, Hervé Kovacic
2and Sylvia Pietri
11 Aix Marseille Univ, CNRS, UMR 7273, ICR, SMBSO, 13013 Marseille, France
2 Aix Marseille Univ, CNRS, UMR 7051, INP, 13005 Marseille, France
* Correspondence: caroline.delehedde@univ-amu.fr
† Presented at the 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery, Barcelona, Spain, 15–17 May 2019.
Published: 19 August 2019
Keywords: metformin; phenolics; hybrid molecules; glioblastoma; cytotoxicity; oxidative stress
Glioblastoma is the most common cerebral tumor in adults. The median survival of glioblastoma
patients is 12 months. Metformin is a biguanide used as a standard clinical drug for the treatment of
type 2 diabetes. Recently, several studies revealed that the risk of cancer development was
significantly reduced for diabetic patients treated with metformin compared to those treated with
insulin or sulfonylureas [1]. Even if metformin acts as an antitumoral agent, it is a nontoxic molecule
with IC
50around 10 mM in cancer cells. In cancer research, naturally occurring phenolic acids are
well known to be useful antioxidant agents and allow the inhibition of the migration and adhesion
of cancer cells [2]. Moreover, a recent study [3] on nitrones combined with phenolic acids has shown
that phenolic acids keep their antioxidant properties even if they are coupled with another molecule.
The purpose of this study is to design new molecules combining metformin and a phenolic acid to
improve the cytotoxicity on cancer cells.
A series of hybrid molecules was then synthesized. For each molecule, IC
50on glioblastoma cell
lines (U87 and U251) and on human dermal fibroblasts was tested. After this first screening, the
mechanisms through which the best hybrid molecules act on cancer cells were studied and compared
with those of metformin. Finally, the study of cytotoxicity on cancer stems cells of glioblastoma,
GBM6, and GBM9 revealed that metformin-derived molecules may also restrict the growth of stem
cells. As cancer stem cells are one of the causes of tumor resistance [4], metformin hybrid molecules
may become a novel therapeutic option to treat glioblastoma.
References
1. Zi, F.; Zi, H.; Li, Y.; He, J.; Shi, Q.; Cai, Z. Metformin and cancer: An existing drug for cancer prevention and therapy. Oncology Lett. 2018, 15, 683–690.
2. Bouzaiene, N.N.; Jaziri, S.K.; Kovacic, H.; Chekir-Ghedira, L.; Ghedira, K.; Luis, J. The effects of caffeic, coumaric and ferulic acids on proliferation, superoxide production, adhesion and migration of human tumor cells in vitro. Eur. J. Pharmacol. 2015, 766, 99–105.
3. Cassien, M.; Petrocchi, C.; Thétiot-Laurent, S.; Robin, M.; Ricquebourg, E.; Kandouli, C.; Asteian, A.;
Rockenbauer A.; Mercier, A.; Culcasi, M.; et al. On the vasoprotective mechanisms underlying novel β-phosphorylated nitrones: Focus on free radical characterization, scavenging and NO-donation in a biological model of oxidative stress. Eur. J. Med. Chem. 2016, 119, 197–217.
Proceedings 2019, 22, 83 2 of 2
4. Tchoghandjian, A.; Baeza-Kallee, N.; Beclin, C.; Metellus, P.; Colin, C.; Ducray, F.; Adélaïde, J.; Rougon, G.; Figarella-Branger, D. Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. Ann. Surg. Oncol. 2012, 19, S608–S619.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
